α-defensin 1-3 and α-defensin 4 as predictive markers of imatinib resistance and relapse in CML patients

Disease Markers

Volumn 30, Issue 5, 2011, Pages 221-227

  Etienne, Gabriel ^a,b   Dupouy, Maryse ^a   Costaglioli, Patricia ^c   Chollet, Claudine ^d   Lagarde, Valérie ^a   Pasquet, Jean Max ^a   Reiffers, Josy ^b   Garbay, Bertrand ^c   Mahon, François Xavier ^a,d   Turcq, Béatrice ^a  

^a INSERM   (France)

^b INSTITUT BERGONIÉ   (France)

^c UNIVERSITÉ DE BORDEAUX   (France)

^d HAUT LÉVÊQUE HOSPITAL   (France)

Author keywords

Chronic myeloid leukaemia; imatinib resistance; predictive biomarker; defensin

Indexed keywords

ALPHA DEFENSIN; ALPHA DEFENSIN 1; ALPHA DEFENSIN 2; ALPHA DEFENSIN 3; ALPHA DEFENSIN 4; BCR ABL PROTEIN; IMATINIB; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DISEASE MARKER; DRUG TREATMENT FAILURE; GENE EXPRESSION PROFILING; GENETIC TRANSCRIPTION; HUMAN; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; PREDICTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT RESPONSE;

EID: 79960700925     PISSN: 02780240     EISSN: 18758630     Source Type: Journal    
DOI: 10.3233/DMA-2011-0777     Document Type: Article

References (19)

1. Y. Arimura, J. Ashitani, S. Yanagi, M. Tokojima, K. Abe, H. Mukae et al., Elevated serum beta-defensins concentrations in patients with lung cancer, Anticancer Research 24 (2004), 4051-4057. (Pubitemid 40468706)
2. R.S. Bullard, W. Gibson, S.K. Bose, J.K. Belgrave, A.C. Ead-dy, C.J. Wright et al., Functional analysis of the host defense peptide Human Beta Defensin-1: new insight into its potential role in cancer, Molecular Immunology 45 (2008), 839-848. (Pubitemid 47505263)
3. M. Colombat, M.P. Fort, C. Chollet, G. Marit, C. Roche, C. Preudhomme et al., Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment, Haematologica 91 (2006), 162-168.
4. G.Q. Daley, R.A. Van Etten and D. Baltimore, Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome, Science 247 (1990), 824-830.
5. N. Droin, J.B. Hendra, P. Ducoroy and E. Solary, Human defensins as cancer biomarkers and antitumour molecules, Journal of proteomics 72 (2009), 918-927.
6. N. Droin, A. Jacquel, J.B. Hendra, C. Racoeur, C. Truntzer, D. Pecqueur et al., Alpha-defensins secreted by dysplasic gran-ulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia, Blood 115 (2010), 78-88.
7. B.J. Druker, F. Guilhot, G. O'Brien, I. Gathmann, H. Kantar-jian, N. Gattermann et al., Five-year follow-up of patients receiving imatinib for chronic myeloid leukaemia, New England Journal of Medicine 355 (2006), 2408-2417. (Pubitemid 44903745)
8. T. Ganz, M.E. Selsted and R.I. Lehrer, Defensins, European Journal of Haematology 44 (1990), 1-8.
9. A. Hagberg, U. Olsson-Stromberg, U. Wickenberg-Bolin, H. Göransson, A. Isaksson, M. Bengtsson et al., Gene expression analysis identifies a genetic signature potentially associated with response to α-IFN in chronic phase CML patients, Leukemia Research 31 (2007), 931-938. (Pubitemid 46856726)
10. D.A. Holterman, J.I. Diaz, P.F. Blackmore, J.W. Davis, P.F. Schellhammer, A. Corica et al., Overexpression of alpha-defensin is associated with bladder cancer invasiveness, Uro-logic Oncolology 24 (2006), 97-108. (Pubitemid 43340166)
11. H. Kantarjian, C. Sawyers, A. Hochhaus, F. Guilhot, C. Schif-fer, C. Gambacorti-Passerini et al., Hematologic and cytoge-netic responses to imatinib mesylate in chronic myelogenous leukaemia, New England Journal of Medicine 346 (2002), 645-652. (Pubitemid 34815868)
12. M.E Klotman and T.L. Chang, Defensins in innate antiviral immunity, Nature Reviews Immunology 6 (2006), 447-456.
13. J.V. Melo and M.W. Deininger, Biology of chronic myeloge-nous leukemia - signaling pathways of initiation and transformation, Hematology/Oncology Clinics of North America 18 (2004), 545-568. (Pubitemid 38969131)
14. M.J. Nam, M.K. Kee, R. Kuick and S.M. Hanash, Identification of defensin alpha6 as a potential biomarker in colon adenocarcinoma, The Journal of Biological Chemistry 280 (2005), 8260-8265. (Pubitemid 40349727)
15. M.O. Nowicki, P. Pawlowski, T. Fischer, G. Hess, T. Pawlows-ki and T. Skorski, Chronic myelogenous leukaemia molecular signature, Oncogene 22 (2003), 3952-3963. (Pubitemid 36819669)
16. A. Quintás-Cardama, M. Hagop, H. Kantarjian and J.E. Cortes, Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia, Cancer Control 16 (2009), 122-131.
17. J.E. Sokal, E.B. Cox, M. Baccarani, S. Tura, G.A. Gomez, J.E. Robertson et al., Prognostic discrimination in "good-risk" chronic granulocytic leukemia, Blood 63 (1984), 789-799. (Pubitemid 14141296)
18. M. Talpaz, R.T. Silver, B.J. Druker, J.M. Goldman, C. Gambacorti-Passerini, F. Guilhot et al., Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study, Blood 99 (2002), 1928-1937. (Pubitemid 34525471)
19. D. Yang, A. Biragyn, L.W. Kwak and J.J. Oppenheim, Mammalian defensins in immunity: more than just microbicidal, Trends in Immunology 23 (2002), 291-296. (Pubitemid 34628771)